Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Free Report) – Equities research analysts at Wedbush lowered their FY2025 earnings per share estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.84) per share for the year, down from their previous estimate of ($0.97). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.
Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.
Read Our Latest Stock Analysis on Werewolf Therapeutics
Werewolf Therapeutics Trading Down 0.9 %
Shares of NASDAQ:HOWL opened at $1.16 on Monday. The company has a market cap of $52.00 million, a P/E ratio of -0.76 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a 1 year low of $1.03 and a 1 year high of $6.89. The stock’s fifty day moving average price is $1.34 and its 200-day moving average price is $1.79.
Institutional Trading of Werewolf Therapeutics
Hedge funds have recently bought and sold shares of the company. Walleye Capital LLC increased its position in Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares in the last quarter. PFM Health Sciences LP increased its position in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares in the last quarter. State Street Corp increased its position in Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares in the last quarter. XTX Topco Ltd purchased a new stake in Werewolf Therapeutics in the third quarter worth about $45,000. Finally, Barclays PLC increased its position in Werewolf Therapeutics by 130.1% in the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after buying an additional 30,990 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Further Reading
- Five stocks we like better than Werewolf Therapeutics
- Insider Buying Explained: What Investors Need to Know
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Market Cap Calculator: How to Calculate Market Cap
- 3 Must-Own Stocks to Build Wealth This Decade
- How Technical Indicators Can Help You Find Oversold Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.